CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X. - Wikidata - awgldk - TriplyDB

CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.

CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.

http://www.wikidata.org/entity/Q40580426

about

CRISPR/Cas9 and cancer targets: future possibilities and present challenges Application of CRISPR/Cas9 Technology to HBV Future Therapy for Hepatitis B Virus: Role of Immunomodulators Genome editing and the next generation of antiviral therapy.Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape.Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense.Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus.Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9.CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.Anti-HIV-1 potency of the CRISPR/Cas9 system insufficient to fully inhibit viral replication.CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape.Inactivation of Cancer Mutations Utilizing CRISPR/Cas9.Therapeutic applications of CRISPR RNA-guided genome editing.Therapeutic gene editing: delivery and regulatory perspectives Virus-host interplay in hepatitis B virus infection and epigenetic treatment strategies.CRISPR/Cas9: at the cutting edge of hepatology.Suppression of HBV replication by the expression of nickase- and nuclease dead-Cas9.Cure Strategies for Hepatitis B Virus: The Promise of Immunotherapy.Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus.New horizon for radical cure of chronic hepatitis B virus infection.CRISPR/Cas9-Mediated Immunity to Geminiviruses: Differential Interference and Evasion.Genome editing technologies to fight infectious diseases.CRISPR/Cas9-Advancing Orthopoxvirus Genome Editing for Vaccine and Vector Development.CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy.Gene Therapy for Chronic HBV-Can We Eliminate cccDNA?Drugs in Development for Hepatitis B.Detection of hyper-conserved regions in hepatitis B virus X gene potentially useful for gene therapy.

P2860

Q26769907-55FF5331-A251-4652-9D6D-14ED02953766 Q26779150-61947026-CDCF-4C13-83F6-8F3022426259 Q28078148-4A9525A5-2542-4F5B-BDFE-740499ADF32E Q34529971-152771F3-F4BF-4AC9-B0D6-1FC5AFE7CE8A Q36216276-102FE050-4222-4ACA-955C-53D9B74B43BE Q36730743-569B5FEA-1A9B-4A1E-9FEE-F24C8D13266D Q36951290-2CE0F10F-6E7D-41C1-83BC-B0CD9FD00DBE Q37714431-0692E3F6-118A-4E76-9E75-D593A8215E78 Q38618922-BA919556-F6DF-436F-8ED0-2A8E998AC0D2 Q38765734-27F3D103-D809-4E13-B2F5-FD423E13AA27 Q38800708-6A594D26-87BE-4555-8BD9-1007BE74CB5B Q38826299-DF13424E-B168-4FE8-BB2F-8DAE6E24C11E Q38937607-4E0AEDF0-769C-4E5D-A6C3-476978628C10 Q39230418-6C665BCD-8C25-4795-8DBD-FE8A786ADACA Q39272853-A1EBC550-4BFB-40B6-A778-4BCDE1045E31 Q39294371-DBE239A9-02F1-4915-B727-D09D74A3D345 Q40112750-F88D0AC6-5B66-43B7-8231-315A784C3450 Q40306554-2641918E-97BB-471F-AEE5-02C09B26BAAA Q40530374-4833FDCF-0B8F-4FEA-A597-0DC38C543719 Q40593364-7312DE5F-35A2-46D9-A950-712FFC81E5D8 Q40659541-12F352AB-7470-4A15-A6E8-45D33710AB09 Q47392998-8753F7BE-878B-497A-A270-766576BE6B53 Q47549689-8E6AB832-BC2A-46A0-B9C1-7EA4E106890E Q47553089-1282AB08-7513-4E88-9C11-AEE7D57E9A0B Q52431500-93E76AEA-84EE-4D4A-BE1F-BCBB48783B06 Q52764230-F238D6E6-1121-4EA8-8F23-43F87FA0F663 Q55259180-89DDF1C3-5077-4530-814E-86815E7F184B

P2860

CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.

http://www.wikidata.org/entity/Q40580426

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.

@en

type

label

CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.

@en

prefLabel

CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.

@en

P1433

Q40580426-6F53F06D-C3C5-4CE6-B210-2C34D48795B9

P1476

Q40580426-8137401D-3F82-4430-A7EF-A9B52C279158

P2093

Q40580426-4609CAAC-805B-469F-A87E-02F98987FCEB

Q40580426-4E1E28D8-C949-4A2B-A9DD-F6B8284BF306

Q40580426-80BA5589-ADFD-426E-B82C-C458541FCB11

Q40580426-9A99A32D-76BA-4963-957E-9C9DF0E86AFF

Q40580426-AD5AE861-4840-437C-8EED-A10250466F02

Q40580426-BB7E4689-DA7D-4F51-BD9B-BF8F9A9BF4F3

Q40580426-BC161E61-4458-4643-B53C-686CEDA233D9

Q40580426-C2F4B4A3-07FA-4F70-99DC-D661252D4FFC

P2860

Q40580426-034E3FA9-CD69-40C3-88CE-B00FD856F632

Q40580426-08201561-3A77-4805-B69F-09BEF30E3D20

Q40580426-085AA269-0EA9-4FAA-9A4A-737EF392538A

Q40580426-08B04115-DE0E-462B-81D3-E52ECAA3A7C0

Q40580426-0956E532-7DC1-49DD-A103-BF1ED1D836F6

Q40580426-0F65461D-918C-4EE1-A5B9-06DB6F9E2350

Q40580426-178E884F-3C59-444A-AF8E-4AA50E0000BF

Q40580426-18C3177B-B98D-4FD2-886D-60D1F4F0F019

Q40580426-1CB7B16F-4F4C-4C37-8E7C-9B22F5603CDA

Q40580426-1E8E15E3-5061-4793-9D23-FAB679363106

P2888

Q40580426-7FE0CF4C-8ADA-464C-8EA1-9105B219051C

P304

Q40580426-09574AFB-A987-476E-8794-D125DC2AE220

P31

Q40580426-27E43AA4-C619-41FD-87FF-2437C56BC556

P356

Q40580426-9B064460-C608-471E-97BB-BD1AB118BD2C

P407

Q40580426-E8202FC8-E511-41EB-A20F-D36D2DA26D70

P478

Q40580426-DC91F0C9-BD5B-4C02-A599-ACD5C2DDC8F9

P50

Q40580426-5DB50E5C-8272-46A9-A3E1-00241CC84A90

Q40580426-6E5E4B59-7696-481D-9E13-74D2F9F874EE

Q40580426-A2842158-00E9-44EF-858A-0E7CC4837491

P577

Q40580426-5F2B3E21-66D8-4BE4-BC68-D3233AE6F809

P5875

Q40580426-73D44195-8321-48FC-A12C-2CD6F7B18BD0

P698

Q40580426-09BE48FE-7ADC-4CC4-A1EF-9B0C943C6305

P921

Q40580426-DCC882D2-CE76-49C2-87DE-9268AFEF332C

P932

Q40580426-A9DE5749-630D-43E3-86BA-C49D130100D8

P356

P1433

Scientific Reports

P1476

CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X

@en

P2093

Daniela Indenbirken

http://www.w3.org/2001/XMLSchema#string

Jan Chemnitz

http://www.w3.org/2001/XMLSchema#string

Jan-Hendrik Bockmann

http://www.w3.org/2001/XMLSchema#string

Joachim Hauber

http://www.w3.org/2001/XMLSchema#string

Julian Schulze zur Wiesch

http://www.w3.org/2001/XMLSchema#string

Madina Karimova

http://www.w3.org/2001/XMLSchema#string

Niklas Beschorner

http://www.w3.org/2001/XMLSchema#string

Stefan Lüth

http://www.w3.org/2001/XMLSchema#string

P2860

Highly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice

The enigmatic X gene of hepatitis B virus

Multiplex genome engineering using CRISPR/Cas systems

Hepatitis B: future curative strategies

Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach

Development and applications of CRISPR-Cas9 for genome engineering.

ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering

CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering

Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity

High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells

P2888

P304

13734

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SREP13734

http://www.w3.org/2001/XMLSchema#string

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Werner Dammermann

P577

2015-09-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281516019

http://www.w3.org/2001/XMLSchema#string

P698

26334116

http://www.w3.org/2001/XMLSchema#string

P921

P932

4558539

http://www.w3.org/2001/XMLSchema#string